Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout

From the College  |  Issue: October 2016  |  October 11, 2016

Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout

We read the case report by Dr. Diana Girnita and colleagues (“Severe Refractory Gout: What options are left when pegloticase fails?” The Rheumatologist, August 2016) with interest. A case is reported of a subject with 20 years of chronic refractory gout who failed to respond to pegloticase therapy, and the potential roles of anti-drug antibodies or genetics are discussed. We would like to point out another possible—and we believe more likely—explanation for the findings in this case.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As opposed to the claim of Dr. Girnita that “all patients given pegloticase initially had significant decreases in their PUA,” a review of the database from the randomized clinical trials of pegloticase in chronic refractory gout indicates that two of the 85 subjects (2.4%) receiving 8 mg of pegloticase every two weeks failed to reduce their uric acid levels significantly two weeks after initial treatment. Following subsequent infusions, these subjects also had no significant lowering of their uric acid levels and were categorized as nonresponders. These results indicate that a small fraction of subjects fail to respond to pegloticase. Dr. Girnita suggests this might be related to the development of anti-drug antibodies as we previously reported1 or the possibility of a role for genetic alterations of uric acid transporters. However, a more detailed analysis of these two subjects suggests a different interpretation.

Although neither of these subjects exhibited significant urate lowering two weeks post infusion, each manifest very significant lowering of plasma uric acid 24 hours post infusion (1.03 mg/dL and 1.95 mg/dL, respectively). Moreover, each exhibited a quite low peak pegloticase level after the initial infusion (0.6 and 0.9 ug/mL), whereas the mean peak level in pegloticase treated subjects was 1.4+/-0.1 ug/mL.1 Because the mean terminal half-life of pegloticase is 214 hours (8.9 days), it’s not surprising that these subjects would have very little pegloticase present two weeks after the infusion (0 ug/mL, 0 ug/mL, respectively) and, therefore, minimal urate lowering activity. The explanation of the altered pharmacokinetics in these two subjects is not certain, but weight and related expanded volume of distribution could have contributed because both subjects were quite large, weighing 137 kg (BMI 38.9) and 109 kg (BMI 37.7), respectively. We were not told of the weight or BMI of the subject in the Girnita report. It is unlikely that pre-formed anti-drug antibodies played a role because they were not detected in either subject before treatment. It is possible, however, that the early development of anti-drug antibodies played a role in one subject because anti-pegloticase antibodies at a titer of 1:2430 were detected in this subject two weeks after the first infusion.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline ArthritisOther Rheumatic Conditions Tagged with:failureGoutpegloticasepharmacokineticssuccessThe RheumatologisttherapyTreatment

Related Articles

    Treatment Options for Severe Refractory Gout When Pegloticase Fails

    August 12, 2016

    Pegloticase is a new alternative therapy for patients with severe, refractory gout unresponsive to other urate-lowering agents. The goal of this therapy is to reduce disease burden, tophi size and frequency of flares and to improve quality of life when other treatments have failed. Persistent lowering of plasma uric acid (PUA) to less than 6…

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Lost and found

    Understanding the Role of Uric Acid in Gout

    September 6, 2022

    From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences